Physician clinical research has undergone a structural transformation — one that five quarters of ZoomRx behavioral tracking data now documents in precise, measurable terms. The change is not a preference shift. It is a mode shift.
The traditional research workflow — scanning medical journals, visiting manufacturer sites, navigating to clinical decision support tools, assembling evidence link by link — has given way to a faster, more direct approach. Physicians now go directly to AI or CDS tools with a specific question and expect an immediate synthesis. ZoomRx calls this the "query-to-resolve" model, and the behavioral data confirms it has arrived at scale.
Between Q1 2025 and Q1 2026, medical AI platforms grew 491% in time share among ZoomRx's Heme/Onc panel — but grew 686% in visit share. The gap reveals a critical dynamic: physicians visit AI far more often, but each session resolves rapidly. AI is gaining on volume, not duration. Per-visit duration on AI platforms now matches journal visits: roughly 41 seconds each.
Journal visits tell a parallel story. Visit share held steady, but time-per-visit compressed from 78.5 seconds to 41.5 seconds. Physicians still go to journals — but they retrieve information faster, likely because AI has already synthesized the key findings and they are cross-referencing.
Among dedicated medical AI platforms, OpenEvidence has emerged as the dominant tool for Heme/Onc clinical research. It surged from rank #15 in physician research time share (Q1 2025) to rank #2 (Q1 2026), trailing only NCCN. Three in five physician AI users identify it as their primary platform — approximately 2.5 times the rate of ChatGPT.
The attitudinal data explains the behavioral pattern. Most physicians (61%) systematically cross-reference AI outputs with other sources — a "don't trust but verify" workflow engineered in response to recognized inaccuracies. Physicians use AI for its speed and synthesis capability, catch the manageable errors, and keep moving. Two-thirds of frequent users report that AI inaccuracies have never negatively impacted a clinical decision.
Suggested Read: Physician AI Adoption Has Crossed Every Generation. The Data Proves It.
As the research workflow has compressed, brand websites have absorbed the displacement. Pharma brand sites lost 57% of time share and 55% of visit share in the same twelve-month window. Per-visit duration dropped to 39.8 seconds — the lowest of any category ZoomRx tracks.
Standard web analytics will not show you this shift clearly. Impression counts remain stable. Click-through rates look normal. What is declining is sustained physician engagement — and that loss is migrating directly to the platforms where query-to-resolve now happens.
ZoomRx Media Tracking was built to surface exactly this kind of behavioral intelligence — capturing the actual digital journey of verified Heme/Oncs across every channel, including Med AI platforms that traditional analytics cannot see. The full white paper details platform-level breakdowns, site-level rank movements, and the strategic implications for pharma marketing and content teams.